Key Highlights
- Futura Medical plc LSE:FUM gained 8.31% on 16 September 2026, according to the market snapshot provided.
- The stock remains highly event-driven following Futura's launch of a formal sale process and parallel asset and licensing review earlier this month.
- The company has also raised new funds while working to address its near-term cash requirements.
- Eroxon remains the core commercial product, with a new US commercial partner now responsible for distribution following the end of the previous US arrangement.
- Eroxon Intense has received European and UK launch clearance, while US regulatory clearance is expected in Q4 2026.
- Futura's latest interim results showed £1.62 million revenue, although £1.40 million came from a settlement payment, while underlying Revenue was only £0.21 million.
- Cash preservation and the company's ability to secure additional funding remain central issues for investors.
Why Has Futura Medical Stock Risen 8.31% Today?
Futura Medical LSE:FUM has attracted renewed attention after rising 8.31% on 16 September 2026. The move comes during an unusually important period for the company, with several strategic and financial developments taking place simultaneously.
The biggest recent catalyst is Futura's decision to launch a formal sale process alongside a parallel strategic review of its Assets and licensing opportunities. The process was announced on 3 September and is being conducted while the company continues to develop and commercialise its sexual-health portfolio.
The company has also recently completed a fundraising process designed to strengthen its financial position. These developments have made LSE:FUM particularly sensitive to changes in trading sentiment as investors assess the potential implications of the strategic review, future funding and commercialisation of Eroxon.
Why Is LSE:FUM in Focus for Investors?
Futura's principal commercial asset is Eroxon, a topical gel for erectile dysfunction. The product is already commercially available in multiple markets and uses a topical application and evaporative mechanism intended to stimulate sensory receptors and support an erection.
The company's strategy is now focused on rebuilding commercial momentum around Eroxon while developing additional products.
Futura appointed Market Performance Group as its new US commercial partner from 1 September 2026 after ending its previous arrangement. The company described the new agreement as providing a route to rebuilding momentum in the US, one of the world's largest erectile-dysfunction markets.
This makes US sales performance one of the most important indicators for the next stage of the LSE:FUM story.
What Is Happening With Eroxon in the US?
The US market is particularly important because Futura previously generated Royalty income from Eroxon sales there.
The company ended its previous commercial relationship and entered into an agreement with Market Performance Group to distribute Eroxon in the US. The transition period ran through the summer, with the new commercial partner taking over from 1 September 2026.
Investors will therefore be watching whether the new distribution model can improve product availability, Marketing execution and sales momentum.
The transition also explains why recent reported revenue does not necessarily provide a clean picture of Futura's underlying commercial potential.
Could Eroxon Intense Become Another Growth Driver?
Eroxon Intense is another important catalyst.
Futura completed a home-user study involving 223 men, comparing the new formulation with the existing Eroxon product. The company reported positive results, including stronger sensory effects from the Intense formulation.
In July 2026, Eroxon Intense received clearance for launch across the European Economic Area and the UK. The company has been preparing production and expects initial markets to begin receiving the product from early 2027.
The US regulatory process remains another milestone, with the company currently expecting clearance in Q4 2026.
That creates a sequence of potential commercial milestones extending into 2027.
What Do Futura Medical's Latest Financial Results Show?
Futura's six months to 30 June 2026 produced revenue of £1.62 million, compared with £1.00 million in the corresponding period.
However, the composition of that revenue is important. Approximately £1.40 million came from the settlement with its former US commercial partner, while underlying revenue was approximately £0.21 million, primarily comprising royalty income from US Eroxon sales.
The operating loss narrowed to £1.20 million, compared with £6.72 million in the prior-year period. Administrative expenses also fell 17% to £2.19 million, showing the impact of the company's cost-reduction programme.
However, cash remained a major issue. Cash and equivalents were approximately £1.24 million at 30 June 2026, and the company said its existing resources, without additional funding, were expected to support operations only until around October 2026.
Why Is the Strategic Review Important for LSE:FUM?
The strategic review adds another major variable to the stock.
Futura is examining strategic Options for the Business while simultaneously reviewing its assets and licensing opportunities. The process potentially covers the wider company, individual assets or commercial arrangements, although the outcome remains uncertain.
For investors, the important point is that the company's future structure and financing model are currently being evaluated.
Recent takeover-related disclosure filings also show that Futura has become subject to increased market disclosure activity following the strategic process. These filings record positions or dealings but do not themselves establish that a transaction will occur.
What Other Products Could Add Value to Futura Medical?
Beyond Eroxon and Eroxon Intense, Futura is developing WSD4000, a female sexual-health programme.
The company reported encouraging early feasibility, home-use and placebo-study results. Its home-use testing showed that 80% of participating women said the gel improved their overall sexual experience. Futura has begun discussions with potential commercial partners across several regions.
The programme remains earlier-stage than Eroxon, meaning additional clinical development and funding will be required before any potential commercial launch.
Futura currently outlines a potential targeted market launch around Q1 2028 under a new commercial model, subject to development and funding requirements.
What Should Investors Watch After Today's 8.31% Rise?
Strategic review: Progress and any resulting transaction or licensing developments could materially affect LSE:FUM.
Funding: The company's cash requirements make financing an important near-term issue.
US Eroxon sales: The performance of the new commercial Partnership will be closely watched.
Eroxon Intense: US regulatory progress and preparation for the first 2027 launches are important upcoming milestones.
WSD4000: Further clinical and commercial-partner developments could broaden Futura's product portfolio.
Underlying revenue: Investors will want to distinguish recurring product and royalty income from one-off payments.
What Does Today's 8.31% Gain Mean for LSE:FUM?
The 8.31% rise in Futura Medical LSE:FUM on 16 September 2026 comes as the company enters a particularly important strategic period.
Eroxon remains the core commercial asset, while the new US distribution arrangement, Eroxon Intense, WSD4000 and the strategic review provide several potential sources of future development. At the same time, the latest financial figures show why funding and Recurring Revenue remain central to the company's outlook.
The immediate focus for investors is therefore likely to remain on the strategic process, cash position, US commercial performance and the progression of Eroxon Intense toward wider market launch.






Please wait processing your request...